REVIEW ARTICLE
CAQ Corner: Genetic liver disease
James E. Squires,
Simon P. Horslen,
Corresponding Author
James E. Squires
Division of Gastroenterology, Hepatology and Nutrition, UPMC Children’s Hospital of Pittsburgh, Pittsburgh, Pennsylvania, USA
Correspondence
James E. Squires, Division of Gastroenterology, Hepatology and Nutrition, UPMC Children’s Hospital of Pittsburgh, One Children’s Hospital Drive, 6th Floor FP, 4401 Penn Avenue, Pittsburgh, PA 15224, USA.
Email: [email protected]
Search for more papers by this authorSimon P. Horslen
Division of Gastroenterology, Hepatology and Nutrition, UPMC Children’s Hospital of Pittsburgh, Pittsburgh, Pennsylvania, USA
Search for more papers by this authorJames E. Squires,
Simon P. Horslen,
Corresponding Author
James E. Squires
Division of Gastroenterology, Hepatology and Nutrition, UPMC Children’s Hospital of Pittsburgh, Pittsburgh, Pennsylvania, USA
Correspondence
James E. Squires, Division of Gastroenterology, Hepatology and Nutrition, UPMC Children’s Hospital of Pittsburgh, One Children’s Hospital Drive, 6th Floor FP, 4401 Penn Avenue, Pittsburgh, PA 15224, USA.
Email: [email protected]
Search for more papers by this authorSimon P. Horslen
Division of Gastroenterology, Hepatology and Nutrition, UPMC Children’s Hospital of Pittsburgh, Pittsburgh, Pennsylvania, USA
Search for more papers by this authorFirst published: 04 April 2022
Earn CME and MOC for this article: www.wileyhealthlearning.com/aasld.aspx
CONFLICT OF INTEREST
Simon P. Horslen received grants from Mirum.
REFERENCES
- 1Mazariegos G, Shneider B, Burton B, Fox IJ, Hadzic N, Kishnani P, et al. Liver transplantation for pediatric metabolic disease. Mol Genet Metab. 2014; 111: 418–27.
- 2McKiernan PJ, Ganoza A, Squires JE, Squires RH, Vockley J, Mazariegos G, et al. Evolving trends in liver transplant for metabolic liver disease in the United States. Liver Transpl. 2019; 25: 911–21.
- 3Darwish AA, McKiernan P, Chardot C. Paediatric liver transplantation for metabolic disorders. Part 1: liver-based metabolic disorders without liver lesions. Clin Res Hepatol Gastroenterol. 2011; 35: 194–203.
- 4Arnon R, Kerkar N, Davis MK, Anand R, Yin W, Gonzalez-Peralta RP, et al. Liver transplantation in children with metabolic diseases: the studies of pediatric liver transplantation experience. Pediatr Transplant. 2010; 14: 796–805.
- 5Kowdley KV, Brown KE, Ahn J, Sundaram V. Correction: ACG clinical guideline: hereditary hemochromatosis. Am J Gastroenterol. 2019; 114: 1927.
- 6Salgia RJ, Brown K. Diagnosis and management of hereditary hemochromatosis. Clin Liver Dis. 2015; 19: 187–98.
- 7Stoller JK, Aboussouan LS. Alpha1-antitrypsin deficiency. Lancet. 2005; 365: 2225–36.
- 8de Serres F, Blanco I. Role of alpha-1 antitrypsin in human health and disease. J Intern Med. 2014; 276: 311–35.
- 9Fromme M, Schneider CV, Trautwein C, Brunetti-Pierri N, Strnad P. Alpha-1 antitrypsin deficiency: a re-surfacing adult liver disorder. J Hepatol. 2022; 76: 946–58.
- 10Sveger T, Eriksson S. The liver in adolescents with alpha 1-antitrypsin deficiency. Hepatology. 1995; 22: 514–7.
- 11Sveger T. Liver disease in alpha1-antitrypsin deficiency detected by screening of 200,000 infants. N Engl J Med. 1976; 294: 1316–21.
- 12Patel D, Teckman JH. Alpha-1-antitrypsin deficiency liver disease. Clin Liver Dis. 2018; 22: 643–55.
- 13Chinsky JM, Singh R, Ficicioglu C, van Karnebeek CDM, Grompe M, Mitchell G, et al. Diagnosis and treatment of tyrosinemia type I: a US and Canadian consensus group review and recommendations. Genet Med. 2017; 19: 1380–95.
- 14Couchonnal E, Lion-François L, Guillaud O, Habes D, Debray D, Lamireau T, et al. Pediatric Wilson's disease: phenotypic, genetic characterization and outcome of 182 children in France. J Pediatr Gastroenterol Nutr. 2021; 73: e80–6.
- 15Członkowska A, Litwin T, Dusek P, Ferenci P, Lutsenko S, Medici V, et al. Wilson disease. Nat Rev Dis Primers. 2018; 4: 21.
- 16Roberts EA, Schilsky ML, American Association for Study of Liver Diseases. Diagnosis and treatment of Wilson disease: an update. Hepatology. 2008; 47: 2089–111.
- 17Saroli Palumbo C, Schilsky ML. Clinical practice guidelines in Wilson disease. Ann Transl Med. 2019; 7(Suppl 2): S65.
- 18Henkel SA, Squires JH, Ayers M, Ganoza A, McKiernan P, Squires JE. Expanding etiology of progressive familial intrahepatic cholestasis. World J Hepatol. 2019; 11: 450–63.
- 19van Wessel DBE, Thompson RJ, Gonzales E, Jankowska I, Sokal E, Grammatikopoulos T, et al. Genotype correlates with the natural history of severe bile salt export pump deficiency. J Hepatol. 2020; 73: 84–93.
- 20van Wessel DBE, Thompson RJ, Gonzales E, Jankowska I, Shneider BL, Sokal E, et al. Impact of genotype, serum bile acids, and surgical biliary diversion on native liver survival in FIC1 deficiency. Hepatology. 2021; 74: 892–906.
- 21Brissot P, Pietrangelo A, Adams PC, de Graaff B, McLaren CE, Loreal O. Haemochromatosis. Nat Rev Dis Primers. 2018; 4:18016.
- 22Batts KP. Iron overload syndromes and the liver. Mod Pathol. 2007; 20(Suppl 1): S31–9.
- 23Hakim A, Moll M, Qiao D, Liu J, Lasky-Su JA, Silverman EK, et al. Heterozygosity of the alpha 1-antitrypsin Pi*Z allele and risk of liver disease. Hepatol Commun. 2021; 5: 1348–61.
- 24Schilsky ML. Wilson disease: diagnosis, treatment, and follow-up. Clin Liver Dis. 2017; 21: 755–67.
- 25 European Association for Study of Liver. EASL Clinical Practice Guidelines: Wilson's disease. J Hepatol. 2012; 56: 671–85.
- 26Nagral A, Sarma MS, Matthai J, Kukkle PL, Devarbhavi H, Sinha S, et al. Wilson's disease: clinical practice guidelines of the Indian National Association for Study of the Liver, the Indian Society of Pediatric Gastroenterology, Hepatology and Nutrition, and the Movement Disorders Society of India. J Clin Exp Hepatol. 2019; 9: 74–98.
- 27Leung DH, Narkewicz MR. Cystic fibrosis-related cirrhosis. J Cyst Fibros. 2017; 16(Suppl 2): S50–61.
- 28Stonebraker JR, Ooi CY, Pace RG, Corvol H, Knowles MR, Durie PR, et al. Features of severe liver disease with portal hypertension in patients with cystic fibrosis. Clin Gastroenterol Hepatol. 2016; 14: 1207–15.e3.
- 29Dowman JK, Watson D, Loganathan S, Gunson BK, Hodson J, Mirza DF, et al. Long-term impact of liver transplantation on respiratory function and nutritional status in children and adults with cystic fibrosis. Am J Transplant. 2012; 12: 954–64.
- 30Mendizabal M, Reddy KR, Cassuto J, Olthoff KM, Faust TW, Makar GA, et al. Liver transplantation in patients with cystic fibrosis: analysis of United Network for Organ Sharing data. Liver Transpl. 2011; 17: 243–50.
- 31Clayton RJ, Iber FL, Ruebner BH, McKusick VA. Byler disease. Fatal familial intrahepatic cholestasis in an Amish kindred. Am J Dis Child. 1969; 117: 112–24.
- 32Henkel SAF, Salgado CM, Reyes-Mugica M, Soltys KA, Strauss K, Mazariegos GV, et al. Long-term liver transplant outcomes for progressive familial intrahepatic cholestasis type 1: the Pittsburgh experience. Pediatr Transplant. 2021; 25:e14108.
- 33Okamoto T, Sonoda M, Ogawa E, Ito S, Togawa T, Hayashi H, et al. Long-term outcomes of living-donor liver transplantation for progressive familial intrahepatic cholestasis type 1. J Pediatr Gastroenterol Nutr. 2021; 72: 425–9.
- 34Fellman V, Kotarsky H. Mitochondrial hepatopathies in the newborn period. Semin Fetal Neonatal Med. 2011; 16: 222–8.
- 35Lee WS, Sokol RJ. Mitochondrial hepatopathies: advances in genetics, therapeutic approaches, and outcomes. J Pediatr. 2013; 163: 942–8.
- 36Freeman AJ, Sellers ZM, Mazariegos G, Kelly A, Saiman L, Mallory G, et al. A multidisciplinary approach to pretransplant and posttransplant management of cystic fibrosis-associated liver disease. Liver Transpl. 2019; 25: 640–57.
- 37Valamparampil JJ, Gupte GL. Cystic fibrosis associated liver disease in children. World J Hepatol. 2021; 13: 1727–42.
- 38Molleston JP, Sokol RJ, Karnsakul W, Miethke A, Horslen S, Magee JC, et al. Evaluation of the child with suspected mitochondrial liver disease. J Pediatr Gastroenterol Nutr. 2013; 57: 269–76.
- 39Strauss KA, Ahlfors CE, Soltys K, Mazareigos GV, Young M, Bowser LE, et al. Crigler-Najjar syndrome type 1: pathophysiology, natural history, and therapeutic frontier. Hepatology. 2020; 71: 1923–39.
- 40Strauss KA, Robinson DL, Vreman HJ, Puffenberger EG, Hart G, Morton DH. Management of hyperbilirubinemia and prevention of kernicterus in 20 patients with Crigler-Najjar disease. Eur J Pediatr. 2006; 165: 306–19.
- 41Matsumoto S, Haberle J, Kido J, Mitsubuchi H, Endo F, Nakamura K. Urea cycle disorders-update. J Hum Genet. 2019; 64: 833–47.
- 42Bissell DM, Anderson KE, Bonkovsky HL. Porphyria. N Engl J Med. 2017; 377: 862–72.
- 43Lissing M, Nowak G, Adam R, Karam V, Boyd A, Gouya L, et al. Liver transplantation for acute intermittent porphyria. Liver Transpl. 2021; 27: 491–501.
- 44Summar ML, Mew NA. Inborn errors of metabolism with hyperammonemia: urea cycle defects and related disorders. Pediatr Clin North Am. 2018; 65: 231–46.
- 45Häberle J, Boddaert N, Burlina A, Chakrapani A, Dixon M, Huemer M, et al. Suggested guidelines for the diagnosis and management of urea cycle disorders. Orphanet J Rare Dis. 2012; 7:32.
- 46Baumgartner MR, Hörster F, Dionisi-Vici C, Haliloglu G, Karall D, Chapman KA, et al. Proposed guidelines for the diagnosis and management of methylmalonic and propionic acidemia. Orphanet J Rare Dis. 2014; 9:130.
- 47Haijes HA, Jans JJM, Tas SY, Verhoeven-Duif NM, van Hasselt PM. Pathophysiology of propionic and methylmalonic acidemias. Part 1: complications. J Inherit Metab Dis. 2019; 42: 730–44.
- 48Haijes HA, van Hasselt PM, Jans JJM, Verhoeven-Duif NM. Pathophysiology of propionic and methylmalonic acidemias. Part 2: treatment strategies. J Inherit Metab Dis. 2019; 42: 745–61.
- 49Critelli K, McKiernan P, Vockley J, Mazariegos G, Squires RH, Soltys K, et al. Liver transplantation for propionic acidemia and methylmalonic acidemia: perioperative management and clinical outcomes. Liver Transpl. 2018; 24: 1260–70.
- 50Ewing CB, Soltys KA, Strauss KA, Sindhi R, Vockley J, McKiernan P, et al. Metabolic control and “ideal” outcomes in liver transplantation for maple syrup urine disease. J Pediatr. 2021; 237: 59–64.e1.
- 51Capustin M, Frishman WH. Transthyretin cardiac amyloidosis and novel therapies to treat this not-so-rare cause of cardiomyopathy. Cardiol Rev. 2021; 29: 263–73.
- 52Barreiros AP, Galle PR, Otto G. Familial amyloid polyneuropathy. Dig Dis. 2013; 31: 170–4.
- 53Strauss KA, Carson VJ, Soltys K, Young ME, Bowser LE, Puffenberger EG, et al. Branched-chain alpha-ketoacid dehydrogenase deficiency (maple syrup urine disease): Treatment, biomarkers, and outcomes. Mol Genet Metab. 2020; 129: 193–206.
- 54Park J, Egolum U, Parker S, Andrews E, Ombengi D, Ling H. Tafamidis: a first-in-class transthyretin stabilizer for transthyretin amyloid cardiomyopathy. Ann Pharmacother. 2020; 54: 470–7.
- 55Michalon A, Hagenbuch A, Huy C, Varela E, Combaluzier B, Damy T, et al. A human antibody selective for transthyretin amyloid removes cardiac amyloid through phagocytic immune cells. Nat Commun. 2021; 12:3142.
- 56Gillmore JD, Gane ED, Taubel J, Kao J, Fontana M, Maitland ML, et al. CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis. N Engl J Med. 2021; 385: 493–502.
- 57Ando Y, Coelho T, Berk JL, Cruz MW, Ericzon B-G, Ikeda S-I, et al. Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J Rare Dis. 2013; 8:31.
- 58Yamamoto H, Sambommatsu Y, Ishii M, Shimata K, Isono K, Honda M, et al. Surgical outcomes of domino liver transplantation using grafts from living donors with familial amyloid polyneuropathy. Liver Transpl. 2022; 28: 603–14.
- 59Celik N, Squires RH, Vockley J, Sindhi R, Mazariegos G. Liver transplantation for maple syrup urine disease: a global domino effect. Pediatr Transplant. 2016; 20: 350–1.
- 60Morioka D, Takada Y, Kasahara M, Ito T, Uryuhara K, Ogawa K, et al. Living donor liver transplantation for noncirrhotic inheritable metabolic liver diseases: impact of the use of heterozygous donors. Transplantation. 2005; 80: 623–8.
- 61Pham TA, Enns GM, Esquivel CO. Living donor liver transplantation for inborn errors of metabolism—an underutilized resource in the United States. Pediatr Transplant. 2016; 20: 770–3.
